HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Sunshine Act ushers in new era of physician–industry transparency
-
- Core principles can help patients make informed decisions with confidence Joseph F. Sobanko, MD
- Carboplatin plus pemetrexed increased OS in advanced NSCLC
- AACR inaugurates new leadership
- Amiodarone may increase cancer risk
- Association awards research fellowships
- ASTRO to present three gold medals
- Delay in breast cancer treatment decreased survival in young women
- FDA grants priority review for GA101 as CLL treatment
-
- Genetic variations that alter response to warfarin identified
- Heart-healthy lifestyle cut cancer risk by half
- Institute names associate director
- NCI committee appoints chairman
- Nonmelanoma skin cancer history may increase risk for other malignancies
- Planning tool gives voice to young patients with life-limiting diagnoses Christine A. Zawistowski, MD
- Researcher receives immunology prize
- Routine vena cava filters inappropriate for VTE prophylaxis in bariatric surgery patients
-
- Study: Most spending for high-cost Medicare patients not preventable through better care
- Supreme Court ruling on gene patents viewed as ‘victory for medicine’
- A 43-year-old man with APL develops renal failure
- Hospitalized patients not receiving all VTE prophylaxis doses
- Increased cranial radiation linked to cognitive impairment in childhood ALL survivors
- Smaller-sized brain structure observed in adult survivors of ALL
- Addition of cetuximab to cisplatin doubled response in metastatic breast cancer
- Eculizumab inhibited thrombotic microangiopathy in hemolytic-uremic syndrome
-
- Eliminating high-dose, unnecessary pediatric CT scans could reduce imaging-related cancers by two-thirds
- ACA could increase demand for primary care, exceed supply by 10%
- Azoospermic men face higher cancer risk
- CD4 decline linked to cancer, CVD in virally suppressed patients
- CD22 monoclonal antibody shows promise in ALL
- Chemoradiotherapy complications lower among obese patients with esophageal carcinoma
- Coffee consumption linked to reduced risk for liver cancer
- Combination of asbestos exposure, asbestosis, smoking amplified lung cancer risk
-
- ‘Cone-down’ radiation boost reduced treatment volume without losing tumor control
- Digital health records not upholding promises on lower costs, better care
- Fewer Medicare patients dying in hospitals
- Fitzpatrick skin type independently predicted SCC risk in organ transplant recipients
- HCC risk persists 8 years after HCV eradication
- Ibrutinib safe, effective in mantle cell lymphoma
- Invasion depth impacts metastasis, mortality risk in esophageal carcinoma after resection
- Kaposi’s sarcoma, lymphoma highest during first year of ART
-
- Lambrolizumab shows promise in melanoma
- Low-intensity warfarin reduces bleeding, symptomatic venous thromboembolism after THA
- Medicaid drug selection committees often mismanage COI policies, researchers say
- Most nonmelanoma skin cancers treated surgically, regardless of life expectancy
- Obesity increased prostate cancer risk in men with benign biopsies
- Pemetrexed, erlotinib induce similar responses in metastatic NSCLC
- PFS correlated with OS in urothelial cancer
- Prophylaxis with Factor VIII reduced inhibitor risks in hemophilia A
-
- PTEN status did not alter benefit of adjuvant trastuzumab in HER-2 breast cancer
- Rapid decline in ovarian cancer rates coincides with decreased hormone therapy use
- Report card improved adenoma detection, cecal intubation rate during colonoscopy
- Ridaforolimus reduced mortality, delayed tumor progression in metastatic sarcoma
- Short telomere length linked to reduced survival after cancer
- Tumor grade seen as predictor of survival in patients with chondrosarcomas
- US Hispanics reported low level of skin cancer surveillance behaviors
- VPS45 mutation associated with new immunodeficiency syndrome in children
-
- FDA approves Xgeva to treat giant cell tumor of the bone
- Selumetinib increased PFS, reduced tumor size in uveal melanoma
- Investigational agent shows promise in refractory CLL
- Maintenance pazopanib extends DFS in women with advanced ovarian cancer
- Obinutuzumab, rituximab improved chlorambucil efficacy in CLL
- Addition of bevacizumab to temozolomide, radiation improved outcomes in glioblastoma
- Addition of ganetespib to docetaxel improved response, survival in lung adenocarcinoma
- Bevacizumab did not increase OS in glioblastoma
-
- Bevacizumab plus chemotherapy prolonged OS, PFS in cervical cancer
- Enzalutamide exhibited high PSA response rate, similar efficacy to castration
- Nab-paclitaxel plus gemcitabine may be new standard for metastatic pancreatic cancer
- Outcomes from robotic colorectal cancer resection comparable to laparoscopic surgery
- Radiotherapy showed similar control rates, fewer side effects than dissection
- Sorafenib slowed disease progression in metastatic differentiated thyroid cancer
- Weekly paclitaxel produced fewer toxicities than biweekly schedule
- Induction chemotherapy followed by low-dose radiation/cetuximab appears safe, effective in HPV-associated OPSCC
-
- Two new therapies offer options for treatment of HER-2–positive breast cancer Bonnie Lin Boster, PharmD, BCOP; Neelam K. Patel, PharmD